Efficient screening strategies for severe combined immunodeficiencies in newborns

Maartje Blom1, Robbert G M Bredius2, Miriam van der Burg1

  • 1Laboratory for Pediatric Immunology, Willem-Alexander Children's Hospital, Leiden University Medical Center, Leiden, The Netherlands.

Insights

Newborn screening for Severe Combined Immunodeficiency (SCID), a severe inborn error of immunity, is crucial. Early detection through T-cell receptor excision circle (TREC) testing improves infant survival rates.

Area of Science:

  • Immunology
  • Genetics
  • Public Health

Background:

  • Severe Combined Immunodeficiency (SCID) is a life-threatening inborn error of immunity affecting cellular and humoral immunity.
  • Affected infants typically die within the first year without curative treatment like stem cell or gene therapy.
  • SCID's early asymptomatic nature and improved outcomes with early intervention make it a candidate for newborn screening (NBS).

Purpose of the Study:

  • To review the implementation and optimization of SCID screening in newborn populations.
  • To discuss the impact of T-cell receptor excision circle (TREC) detection in NBS programs.
  • To highlight the importance of efficient, cost-effective screening strategies and international harmonization.

Main Methods:

  • Population-based screening using T-cell receptor excision circle (TREC) detection.
  • Algorithm adjustments and second-tier tests to optimize screening efficiency and reduce false positives.
  • Review of international NBS programs for SCID.

Main Results:

  • Many countries have successfully implemented SCID screening using TREC detection.
  • Optimized screening strategies balance sensitivity and specificity, managing secondary findings effectively.
  • Harmonization of screening terminology facilitates international knowledge sharing.

Conclusions:

  • Newborn screening for SCID is an effective public health strategy.
  • Advancements in testing, including next-generation sequencing, will expand NBS for other inborn errors of immunity.
  • Continued development of screening modalities and treatments promises improved outcomes for infants with IEI.
Abstract